Oncology Drugs

A novel drug aims to break down resistance in hard-to-treat lung and bile duct cancers, with key data set for a major oncology conference.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

A new partnership provides early access to an investigational drug for FAP, offering a potential non-surgical therapeutic option for the first time.

Final trial data shows pralsetinib offers years of survival for RET+ lung cancer, but realizing its full potential hinges on overcoming diagnostic hurdles.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

After a successful shift to a royalty model, the firm reports stronger financials and confirms it is weighing a merger or acquisition.

NASDAQ-listed Bio Green Med Solution abandons its biopharma roots for fire safety, slashing losses but facing new questions about its long-term survival.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

Crinetics Pharmaceuticals aims to disrupt Brazil's acromegaly treatment with Palsonify, a once-daily pill challenging the standard of monthly injections.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

Early trial data for tazbentetol shows promise in treating schizophrenia by rebuilding synapses, a potential paradigm shift in psychiatric medicine.

Weave Bio forms a star-studded advisory board with leaders from Gilead and Takeda to navigate the high-stakes world of AI in drug development.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

Maze Therapeutics posts positive Phase 2 data for its genetic kidney disease drug, but a sharp stock drop reveals investor concerns in a competitive race.

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

Following a record year, Knight Therapeutics is doubling its share repurchase plan. We analyze the strategy, financials, and what it means for investors.